NCCN Standard of Care Guidelines are updated each year with new biomarkers and associated CDx treatment options for all types of cancers. By the end of 2020 non-small cell lung cancer will have 9 molecular biomarkers to test for standard of care. Join us for this event to learn and discuss how in-house Next Generation Sequencing (NGS) and precision medicine programs can improve patient care and help your organization meet ever-evolving guidelines. CE Credits are available for this event. This event is open to all registrants.
By the conclusion of this session you will understand:
1. Review the benefits of next generation sequencing testing for pathologists
2. Summarize the potential improvements to patient care based on bringing next
generation sequencing in-house
This virtual meeting will be conducted within OncomineWorld in our virtual auditorium. OncomineWorld is so much more than your traditional virtual event – you can navigate to many different areas and experience a new level of virtual interactivity. Within OncomineWorld you can…
Dr. Parneet Cheema is an Assistant Professor, at the University of Toronto, and Head of Medical Oncology/Heamatology and cancer research at the William Osler Health System in Brampton/Toronto, Canada. She is an internationally known expert in lung cancer and precision cancer care in which she has conducted numerous clinical trials and published national consensus statements.
Her research focuses on the safe and efficient implementation of advances in personalized medicine in lung cancer and immunotherapy into day-to-day clinical practice. She founded the Osler Immunotherapy for Cancer Program and has worked closely with her pathology colleagues to develop cancer genomics at Osler.
Dr. Ding is currently the System and Core lab director of Molecular Diagnostics in Diagnostic Medicine Institute at Geisinger Health System. She completed her residency in anatomic and clinical pathology at New York University followed by a molecular genetic pathology (MGP) fellowship at the New York-Presbyterian Hospital/Weill Cornell Medical College. She then went back to New York University and completed a hematopathology fellowship. Thereafter, Dr. Ding joined the faculty at the University of Rochester School of Medicine and Dentistry where she also served as the Associate Director of the Molecular Genetic Pathology Unit prior to coming to Geisinger.
My name is Jessica Wilkett-Barnes. I have a background in both law and business with a Masters in Business Administration from Western Kentucky University and a Juris Doctorate from University of Louisville. I have also successfully passes the bar in both Kentucky and Florida. I have been with Norton Healthcare for almost 6 years working at a system level in clinical effectiveness, as an operational leader in our cancer institute and now as the director of operational optimization for Norton Medical group. The Operational Optimization team focuses on operational process improvement, clinical efficiency, new programs/clinics, acquisitions, epic/IT optimization and the overall successful completion of our goals. My email is Jessica.firstname.lastname@example.org.
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events